Insilico Medicine, an AI-based clinical-stage drug discovery company, announced a multi-year, multi-targeted strategic research collaboration with Sanofi on November 8. Under the terms of the agreement, which could be worth up to 
21.5 million covering upfront and target appointment fees to leverage Insilico’s Pharma.AI platform and access a team of interdisciplinary drug discovery scientists to identify, synthesize and advance high-quality lead therapeutic compounds to the development candidate stage.
Additional payments will be made contingent upon the achievement of key research, development and sales milestones, which could total up to $1.2 billion. The collaboration also establishes medium to low tiered royalties for all products developed.
Translated from Insilico Medicine, la dernière start-up choisie par Sanofi pour accélérer la découverte de médicaments grâce à l’IA
